CymaBay Therapeutics Inc. (NASDAQ:CBAY) had its target price lifted by HC Wainwright to $12.00 in a research note issued to investors on Monday, The Fly reports. The firm currently has a “buy” rating on the biopharmaceutical company’s stock. HC Wainwright’s target price would suggest a potential upside of 112.39% from the company’s previous close.

Other analysts also recently issued reports about the company. ValuEngine raised CymaBay Therapeutics from a “sell” rating to a “hold” rating in a research report on Friday, June 2nd. Zacks Investment Research cut CymaBay Therapeutics from a “buy” rating to a “hold” rating in a research report on Monday, April 3rd. Oppenheimer Holdings, Inc. began coverage on CymaBay Therapeutics in a research report on Friday, June 23rd. They issued an “outperform” rating and a $8.00 price target for the company. Finally, Piper Jaffray Companies lifted their price target on CymaBay Therapeutics from $5.00 to $6.50 and gave the company an “overweight” rating in a research report on Friday, March 24th. Two investment analysts have rated the stock with a hold rating and three have assigned a buy rating to the stock. CymaBay Therapeutics has an average rating of “Buy” and a consensus price target of $7.19.

Shares of CymaBay Therapeutics (CBAY) traded up 14.7239% on Monday, reaching $6.4819. The company’s stock had a trading volume of 8,068,986 shares. The stock’s market cap is $186.37 million. CymaBay Therapeutics has a 52-week low of $1.15 and a 52-week high of $7.77. The firm’s 50 day moving average is $4.59 and its 200-day moving average is $3.37.

CymaBay Therapeutics (NASDAQ:CBAY) last released its earnings results on Thursday, May 11th. The biopharmaceutical company reported ($0.20) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.27) by $0.07. The firm had revenue of $4.79 million during the quarter. On average, equities research analysts forecast that CymaBay Therapeutics will post ($0.83) EPS for the current year.

ILLEGAL ACTIVITY NOTICE: This story was originally published by Watch List News and is the sole property of of Watch List News. If you are viewing this story on another website, it was copied illegally and reposted in violation of United States & international trademark and copyright legislation. The original version of this story can be accessed at https://www.watchlistnews.com/cymabay-therapeutics-inc-nasdaqcbay-price-target-raised-to-12-00-at-hc-wainwright/1445348.html.

Several institutional investors have recently made changes to their positions in CBAY. ClariVest Asset Management LLC bought a new position in shares of CymaBay Therapeutics during the first quarter valued at $105,000. LVM Capital Management Ltd. MI boosted its position in shares of CymaBay Therapeutics by 100.0% in the second quarter. LVM Capital Management Ltd. MI now owns 20,000 shares of the biopharmaceutical company’s stock valued at $115,000 after buying an additional 10,000 shares during the period. Acadian Asset Management LLC bought a new position in shares of CymaBay Therapeutics during the first quarter valued at $129,000. TFS Capital LLC bought a new position in shares of CymaBay Therapeutics during the first quarter valued at $169,000. Finally, Renaissance Technologies LLC boosted its position in shares of CymaBay Therapeutics by 97.6% in the first quarter. Renaissance Technologies LLC now owns 231,949 shares of the biopharmaceutical company’s stock valued at $997,000 after buying an additional 114,549 shares during the period. Institutional investors own 36.87% of the company’s stock.

CymaBay Therapeutics Company Profile

CymaBay Therapeutics, Inc is a clinical-stage biopharmaceutical company. The Company is focused on developing therapies to treat metabolic diseases, including serious rare and orphan diseases. The Company’s product candidates include Arhalofenate, MBX-8025 and MBX-2982. Arhalofenate is used to treat gout.

The Fly

Receive News & Ratings for CymaBay Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CymaBay Therapeutics Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.